Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
A-Z
> Inspiring Target:Interleukin 4 Receptor 
Interleukin-4Rα (IL-4Rα), the key receptor of IL-4, has emerged as an ‘inspiring’ target for innovative therapies aimed at treating various inflammatory and oncological diseases. IL-4Rα is a type I transmembrane protein that plays a key role in the molecular pathway that drives a specific immune pattern called type II inflammations.
This pathway is driven by two cytokines: interleukin-4 (IL-4) and interleukin-13 (IL-13). Both cytokines have diverse biological and immunological effects on lymphocytes, dendritic cells and fibroblasts adjustment function. Specifically, these cytokines bind to IL-4Rα to initiate the type II inflammation pathway that includes differentiation of Th2 cells, airway inflammation and mucus production.
IL-4R and cytokines IL-4 and IL-13 are key regulators in humoral and adaptive immunity. This means that an imbalance in either receptor expression or circulating signaling cytokines can be clinically observed. The resultant immune overreaction is initiated by an initial imbalance of TH1 and TH2 differentiation that drives an abnormal secretion of cytokines. Activated Th2 cells release cytokines including IL-4, 13, and 31, which activate downstream B cells to transform and produce immunoglobulin E (IgE) antibodies. In turn, mast cells and basophils are recruited to degranulate and produce inflammatory factors. Simultaneously, the secreted IL-4 and 13 continue to bind to its respective receptors (e. g. IL-4R) that repeatedly promotes TH2 differentiation and subsequent inflammation. This effect is observed through several autoimmune diseases including asthma, eczema, and hay fever, as well as in metastatic tumors.
Native conformation, free protocol shared
High biological activity verified by ELISA/SPR/ BLI
Authentic structure verified by SEC-MALS
Comprehensive products with various tags and species
High purity verified by SDS-PAGE
IL-4 R alpha
IL-4
IL-13 R alpha 1
IL-13 R alpha 2
IL-4 R alpha/IL-13 R alpha 1
| Cat. No. | Species | Product Description | Preorder/Order |
|---|
| Cat. No. | Species | Product Description | Preorder/Order |
|---|
| Cat. No. | Species | Product Description | Preorder/Order |
|---|
| Cat. No. | Species | Product Description | Preorder/Order |
|---|
| Cat. No. | Species | Product Description | Preorder/Order |
|---|
HumanI IL-4 R alpha, Fc Tag (Cat. No. ILR-H5253）on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%
The purity of Cynomolgus IL-4, Fc Tag (Cat. No. IL4-C5259) is more than90%and the molecular weight of this protein is around85-115 kDaverified by SEC-MALS.
>>> [Inspiring Target] IL-4R Alpha, a Potential Drug Target Worth over $10 Billion
[1] Weng, S. Y., Wang, X., Vijayan, S., Tang, Y., Kim, Y. O., Padberg, K., ... & Schuppan, D. (2018). IL-4 receptor alpha signaling through macrophages differentially regulates liver fibrosis progression and reversal. EBioMedicine, 29, 92-103.https://doi.org/10.1016/j.ebiom.2018.01.028.
[2] Husna, S. M. N., Shukri, N. M., Ashari, N. S. M., & Wong, K. K. (2022). IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma. PeerJ, https://doi.org/10, e13444.10.7717/peerj.13444.
[3] Liang, K. L., Yu, S. J., Huang, W. C., & Yen, H. R. (2020). Luteolin attenuates allergic nasal inflammation via inhibition of interleukin-4 in an allergic rhinitis mouse model and peripheral blood from human subjects with allergic rhinitis. Frontiers in pharmacology, 11,291.https://doi.org/10.3389/fphar.2020.00291.
[4] Bankaitis, K. V., & Fingleton, B. (2015). Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. Clinical & experimental metastasis, 32(8), 847-856.https://doi.org/10.1007/s10585-015-9747-9.
[5] Moran, A., & Pavord, I. D. (2020). Anti-IL-4/IL-13 for the treatment of asthma: The story so far. Expert Opinion on Biological Therapy, 20(3), 283-294.
https://doi.org/10.1080/14712598.2020.1714027.
[6] Furue, M. (2020). Regulation of skin barrier function via competition between AHR axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. Journal of Clinical Medicine, 9(11), 3741.https://doi.org/10.3390/jcm9113741.
[7] Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Armentaro, G., Calabrese, C., ... & Vatrella, A.(2022). Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines, 10(6), 974.https://doi.org/10.3390/vaccines10060974.
This web search service is supported by Google Inc.
